List of Antibodies Companies in Illinois - 12

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.

Leica Biosystems is proud to be part of Danaher. Danaher's science and technology leadership puts Leica Biosystems' solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. -- Leica Biosystems Privacy Policy can be found at: https://www.leicabiosystems.com/about/privacy-policy/ The collection, storage, use, disclosure, retention and destruction of data on this page, including any personal data, are all subject, as applicable, to Leica Biosystems' Terms of Use and Privacy Policy. We do not endorse or approve user generated content to promote any other use of our products and will remove any comments or references to such off-label use. We reserve the right to remove a topic or comment at our discretion. By accessing the content, you expressly acknowledge and agree: (1) the content is provided only as a convenience to you and you are accessing the content for your personal educational purposes only; (2) the content may be from a variety of sources over which Leica Biosystems has no control, and should therefore not be interpreted as representing the opinions of, or an endorsement by, Leica Biosystems or its associates; (3) the content is provided to you AS IS, and you release Leica Biosystems of any responsibility or damages you may suffer as a result of the content, including without limitation, any damages resulting from the inaccuracy or unsuitability of the content.

SELAGINE, Inc. develops novel antibody-based biologic eye drops for treatment of immunological or inflammatory ocular surface diseases such as Dry Eye Disease, Sjögren’s syndrome and ocular Graft-versus-Host Disease.

SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.

SparX Biopharmaceutical Corp. is a research-based development-stage biopharmaceutical company, dedicated to the mission of “strengthening human immunity using robust antibody therapies” through the discovery and development of innovative immuno-oncology agents. Equipped with big data analytical techniques, such as machine learning algorithms, SparX extracts potential interactions from large volumes of complex multi-dimensional public information. Mechanistic pharmacological analyses coupled with in vitro and in vivo evaluations using the syngeneic, transgenic and humanized mouse models, enables SparX’s focus on developing novel or best-in-class therapeutics demonstrating substantial advantages over existing therapies. Target discovery and validation has historically been the bottleneck in drug development. SparX combines its sophisticated target discovery platform with an integrated multi-component SAILING™ antibody optimization system and a cutting-edge bi-ADC technology to markedly improve the success rate of empowered antibody drug development. In addition to the integrated antibody discovery platform, SparX has built in-house cGMP facilities of significant capacity to produce clinical and commercial drug products, facilitating its evolution into an integrated and independent biopharmaceutical company.

Sunny Biotechnology Co focuses on the development of polyclonal, monoclonal, secondary antibodies, serum-free media and supplements for stem cell research, peptide synthesis service, and related biotech products for life science research and clinical diagnosis.

Xentria is a venture studio that provides capital and insight into breakthrough science that aligns with our core therapeutic areas to improve the lives of patients and their families. Since our formation in 2020, we've forged authentic partnerships to advance challenging drug development, addressing unmet needs with increased collaboration, tenacity, and partnership. We offer holistic support, enhanced operational efficiency, and long-term partnerships to drive growth and assist in navigating challenges for an increased chance of success.